Abstract:An-An Li, 1, 2 Yu Zhang, 1, 2 Wei-Lai Tong, 1, 2 Jiang-Wei Chen, 1 Shan-Hu Huang, 1 Jia-Ming Liu, 1 Zhi-Li Liu 1, 2 1 Department of Orthopedic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China; 2 Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China Correspondence: Zhi-Li Liu; Jia-Ming Liu, Department of Orthopedic Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang, 330006, People's Republic of China, Tel/Fax +86-791-88693201, Email ; ; Purpose: Pyroptosis plays an important role in the occurrence and progression of many tumors; however, the specific mechanisms involved remain unknown. Here, we construct a pyroptosis-related gene signature that can be used to predict survival prognosis of skin cutaneous melanoma (SKCM) and provide guidance for clinical treatment. Methods: By integrating data from the two databases from the GTEx and TCGA, differentially expressed genes (DEGs) from normal tissues and skin cutaneous tumor tissues were identified. The main signaling pathways and function enrichment of these differential genes were determined. Univariate and multivariate COX regression analysis, and risk score analysis were used to construct a signature to assess its predictive value for overall survival. The mRNA expression of these five genes in melanoma cells was determined by quantitative polymerase chain reaction (qPCR). The pRRophetic algorithm was used to estimate the half-maximal inhibitory concentration (IC50) of chemotherapy drugs in SKCM patients. The expression of multiple immune checkpoint genes also was evaluated. Results: Sixteen DEGs associated with pyroptosis in SKCM and normal skin tissues were identified. Of these, 12 pyroptosis-related DEGs were associated with the prognosis of SKCM. A five-gene signature (GSDMA, GSDMC, IL-18, NLRP6, and AIM2) model was constructed. Patients were divided into high-risk and low-risk groups using the risk scores. Of these, the high-risk group had a worse survival prognosis. There are significant differences in the predicted sensitivity of the high-risk and low-risk groups to chemotherapeutic drugs. In addition, compared with the high-risk group, the low-risk group showed higher expression of PD-1, PDL-1, CTLA-4, LAG-3, and VSIR. Conclusion: In this study, we constructed a novel prognostic pyroptosis-related gene-signature for SKCM. These genes showed good predictive value for patient prognosis and could provide guidance for better treatment of SKCM patients. Keywords: skin cutaneous melanoma, pyroptosis, prognosis, signature, risk model Skin cutaneous melanoma (SKCM) is very aggressive and lethal type of skin cancer. 1 Although melanoma only accounts for about 1% of all skin cancers, the mortality rate is very high, accounting for 90% of all skin cancer deaths. 2 In recent years, the incidence of melanoma has gradually increased, and ultraviolet radiation is one of the main environmental risk factors. Melanoma has a tendency to metastasize in the early stages of disease progression, and even small primary tumors may occur. 3 The most common metastatic sites are lung, liver, brain, and bone. 4 The treatment of SKCM is still based on surgery, adjuvant immunotherapy, and chemotherapy. Although patients with early melanoma have a good prognosis, patients with distant metastases experience a very poor prognosis, with a median survival time of only 6–9 months. 5 Pyroptosis is an inflammatory form of programmed cell death. It was first described in 1992 by A. Zychlinsky in Shigella flexneri-infected macrophages. Unlike apoptosis, pyroptosis is characterized by the release of pro-inflammatory factors and relies on caspase-1 instead of caspase-3, as in apoptosis. Pyroptosis can be induced by the typical caspase-1 inflammasome pathway. 6,7 As the executor of pyroptosis, Gasdermin D (GSDMD) is cleaved by activated caspase-1 into two fragments: the N-terminal domain and the C-terminal domain. The N-terminal fragment shifts to the inner lobe of the plasma membrane, forming a membrane pore with an inner diameter of 10–15 nm. 8,9 Next, the punched membrane further promotes the release of inflammatory factors, causing cell swelling, membrane rupture, and ultimately leading to pyroptosis. Pyroptosis was originally discovered because of its anti-inflammatory effects. Currently, an increasing number of studies have shown that Pyroptosis also plays an important role in the immune microenvironment of tumors. Inflammatory v -Abstract Truncated-

Shikonin triggers GSDME-mediated pyroptosis in tumours by regulating autophagy via the ROS–MAPK14/p38α axis

Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression

Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells

Shikonin promotes ubiquitination and degradation of cIAP1/2-mediated apoptosis and necrosis in triple negative breast cancer cells

System analysis based on the pyroptosis-related genes identifes GSDMD as a novel therapy target for skin cutaneous melanoma

Cbl-b-regulated extracellular signal-regulated kinase signaling is involved in the shikonin-induced apoptosis of lung cancer cells in vitro

Shikonin Mediates Apoptosis through G Protein-Coupled Estrogen Receptor of Ovarian Cancer Cells

Β,β-Dimethylacrylshikonin Induces Mitochondria Dependent Apoptosis Through ERK Pathway in Human Gastric Cancer SGC-7901 Cells.

Shikonin Induces Glioma Necroptosis, Stemness Decline, and Impedes (Immuno)Proteasome Activity

Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis

Shikonin reactivates TSGs GADD45B and PPP3CC to block NSCLC cell proliferation and migration through JNK/P38/MAPK signaling pathways

Shikonin Causes Non-apoptotic Cell Death in B16F10 Melanoma

Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis

Shikonin Induced Program Cell Death through Generation of Reactive Oxygen Species in Renal Cancer Cells

Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling

Saikosaponin‐D induces the pyroptosis of lung cancer by increasing ROS and activating the NF‐κB/NLRP3/caspase‐1/GSDMD pathway

Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells

Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis

Excessive Oxidative Stress in the Synergistic Effects of Shikonin on the Hyperthermia-Induced Apoptosis

In vitro characterization and molecular dynamic simulation of shikonin as a tubulin-targeted anticancer agent

Identification of a Novel Pyroptosis-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Skin Cutaneous Melanoma